Quantification for Antibody-Conjugated Drug in Trastuzumab Emtansine and Application to In Vitro Linker Stability and In Vivo Pharmacokinetic Study in Rat Using an Immuno-Affinity Capture Liquid Chromatography-Mass Spectrometric Method

Quantification for Antibody-Conjugated Drug in Trastuzumab Emtansine and Application to In Vitro Linker Stability and In Vivo Pharmacokinetic Study in Rat Using an Immuno-Affinity Capture Liquid Chromatography-Mass Spectrometric Method

Trastuzumab emtansine (T-DM1, brand name: Kadcyla<sup>®</sup>) is the first FDA-approved antibody-drug conjugate (ADC) for metastatic human epidermal growth factor receptor 2 positive (HER2+) breast cancer. It consists of three components: trastuzumab, an anti-HER2 monoclonal antibody, m...

Full description

Bibliographic Details
Main Authors: Seo-jin Park, Byeong ill Lee, Min-Ho Park, Jangmi Choi, Yuri Park, Min-jae Park, Jeong-hyeon Lim, Jiyu Lee, Sangsoo Hwang, Jeongmin Lee, Young G. Shin
Format: Article
Language:English
Published: MDPI AG 2021-10-01
Series:Applied Sciences
Subjects:
antibody-drug conjugate (ADC)
antibody-conjugated drug (acDrug)
quantification
LC-MS/MS
bioanalysis
non-cleavable linker
Online Access:https://www.mdpi.com/2076-3417/11/20/9437

Similar Items

Similar Items